Shanghai Henlius Biotech, Inc.
HKEX:2696.HK
23.1 (HKD) • At close September 17, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Shanghai Henlius Biotech, Inc. |
Symbool | 2696.HK |
Munteenheid | HKD |
Prijs | 23.15 |
Beurswaarde | 12,581,905,685 |
Dividendpercentage | 0% |
52-weken bereik | 9.6 - 23.45 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Jun Zhu |
Website | https://www.henlius.com |
An error occurred while fetching data.
Over Shanghai Henlius Biotech, Inc.
Shanghai Henlius Biotech, Inc., a biopharmaceutical company, engages in the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases. It offers HANLIKANG, a rituximab injection for treating non-hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis; HANQUYOU, a trastuzumab injection to treat breast and
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (HKD)
Cijfers zijn in miljoenen (HKD)